Indian conglomerate SRF Limited has acquired DuPont’s Dymel pharmaceutical propellants for $20 million in cash, according to reports in the Indian press. SRF, which already has two technical grade HFA-134a plants, plans to build its own cGMP facility to produce pharmaceutical grade propellant. DuPont will supply pharmaceutical grade HFA-134a until the new plant is approved.
SRF Managing Director Ashish Bharat Ram cites expectations of “reasonably robust” growth in the MDI market as one of the company’s incentives for acquiring the Dymel product line.
Read the Economic Times article.
